Trials / Withdrawn
WithdrawnNCT03575078
ARQ761 + PARP Inhibitor in Refractory Solid Tumors
PHASE 1 DOSE ESCALATION TRIAL OF β-LAPACHONE (ARQ761) IN COMBINATION WITH PARP INHIBITOR, OLAPARIB, FOR REFRACTORY, ADVANCED SOLID TUMORS
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Texas Southwestern Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of ARQ761 and a PARP inhibitor, Olaparib
Detailed description
Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of ARQ761 and a PARP inhibitor, Olaparib. This is an exploratory Phase 1 trial evaluating the safety and tolerability of the combination of ARQ761 and Olaparib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ761, Olaparib | ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily |
Timeline
- Start date
- 2018-06-25
- Primary completion
- 2019-05-15
- Completion
- 2019-05-15
- First posted
- 2018-07-02
- Last updated
- 2019-09-25
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03575078. Inclusion in this directory is not an endorsement.